See more : Feutune Light Acquisition Corporation (FLFVU) Income Statement Analysis – Financial Results
Complete financial analysis of Akero Therapeutics, Inc. (AKRO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Akero Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Polished.com Inc. (GOED) Income Statement Analysis – Financial Results
- Axion Ventures Inc. (AXNVF) Income Statement Analysis – Financial Results
- Nihon Kogyo Co., Ltd. (5279.T) Income Statement Analysis – Financial Results
- Southwest Airlines Co. (0L8F.L) Income Statement Analysis – Financial Results
- NITCO Limited (NITCO.BO) Income Statement Analysis – Financial Results
Akero Therapeutics, Inc. (AKRO)
About Akero Therapeutics, Inc.
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 29.00K | 260.00K | 244.00K | 213.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -29.00K | -260.00K | -244.00K | -213.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 141.80M | 85.28M | 81.76M | 64.92M | 37.05M | 11.88M | 3.49M |
| General & Administrative | 31.07M | 29.87M | 19.13M | 15.24M | 8.61M | 1.90M | 1.18M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -98.00K |
| SG&A | 31.07M | 29.87M | 19.13M | 15.24M | 8.61M | 1.90M | 1.08M |
| Other Expenses | 0.00 | 3.86M | 109.00K | 947.00K | 1.90M | -67.94M | 0.00 |
| Operating Expenses | 172.87M | 115.16M | 100.89M | 80.15M | 45.65M | 13.78M | 4.56M |
| Cost & Expenses | 172.87M | 115.16M | 100.89M | 80.15M | 45.65M | 13.78M | 4.56M |
| Interest Income | 24.21M | 3.86M | 109.00K | 947.00K | 1.90M | 0.00 | 0.00 |
| Interest Expense | 3.10M | 739.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 29.00K | 260.00K | 244.00K | 213.00K | -104.00K | 13.78M | 4.98M |
| EBITDA | -148.63M | -111.03M | -100.53M | -78.99M | -45.65M | -68.46M | -232.36K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -172.87M | -115.16M | -100.89M | -80.15M | -45.65M | -13.78M | -4.56M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 21.11M | 3.12M | 109.00K | 947.00K | 1.90M | -67.94M | 0.00 |
| Income Before Tax | -151.76M | -112.03M | -100.78M | -79.21M | -43.76M | -81.71M | -4.56M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -3.12M | -41.00K | -17.00K | 24.00K | -68.10M | -4.98M |
| Net Income | -151.76M | -108.91M | -100.74M | -79.19M | -43.76M | -81.71M | -4.56M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.89 | -2.79 | -2.89 | -2.52 | -2.90 | -3.85 | -0.16 |
| EPS Diluted | -2.89 | -2.79 | -2.89 | -2.52 | -2.90 | -3.85 | -0.16 |
| Weighted Avg Shares Out | 52.57M | 38.98M | 34.83M | 31.46M | 15.07M | 21.22M | 28.56M |
| Weighted Avg Shares Out (Dil) | 52.57M | 38.98M | 34.83M | 31.46M | 15.07M | 21.22M | 28.56M |
Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
-- Initiated Phase 3 SYNCHRONY Outcomes Trial of Lead Candidate Efruxifermin (EFX) in Patients with Compensated Cirrhosis (F4) Due to MASH
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO)
NEW YORK , July 17, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Akero Therapeutics, Inc. (NASDAQ: AKRO) on behalf of the company's shareholders. The investigation seeks to determine whether Akero's directors breached their fiduciary duties in connection...
Akero Therapeutics (AKRO) Moves to Buy: Rationale Behind the Upgrade
Akero Therapeutics (AKRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for potential violations of the federal securities laws.
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
FINAL AKRO DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Akero Therapeutics, Inc. Investors to Join the Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO) and certain of its officers. Class Definition: This lawsuit seeks to...
AKRO Today Is the Last Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit
LOS ANGELES , June 25, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ: AKRO) for violations of §§10(b) and 20(a)...
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO)
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming June 25, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Akero Therapeutics, Inc. (“Akero” or...
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Akero Therapeutics, Inc. - AKRO
NEW YORK , June 24, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Akero Therapeutics, Inc. ("Akero" or the "Company") (NASDAQ: AKRO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or...
AKRO FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – AKRO
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between September 13, 2022 and October 9, 2023, both dates inclusive...
Source: https://incomestatements.info
Category: Stock Reports